|
1
|
Matzuk MM, Kumar TR, Vassalli A,
Bickenbach JR, Roop DR, Jaenisch R and Bradley A: Functional
analysis of activins during mammalian development. Nature.
374:354–356. 1995. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ying SY, Zhang Z, Furst B, Batres Y, Huang
G and Li G: Activins and activin receptors in cell growth. Proc Soc
Exp Biol Med. 214:114–122. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Antsiferova M and Werner S: The bright and
the dark sides of activin in wound healing and cancer. J Cell Sci.
125:3929–3937. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Loomans HA and Andl CD: Intertwining of
Activin A and TGFβ Signaling: Dual roles in cancer progression and
cancer cell invasion. Cancers (Basel). 7:70–91. 2014. View Article : Google Scholar
|
|
5
|
McDowell N, Zorn AM, Crease DJ and Gurdon
JB: Activin has direct long-range signalling activity and can form
a concentration gradient by diffusion. Curr Biol. 7:671–681. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wildi S, Kleeff J, Maruyama H, Maurer CA,
Büchler MW and Korc M: Overexpression of activin A in stage IV
colorectal cancer. Gut. 49:409–417. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gold E and Risbridger G: Activins and
activin antagonists in the prostate and prostate cancer. Mol Cell
Endocrinol. 359:107–112. 2012. View Article : Google Scholar
|
|
8
|
Loumaye A, de Barsy M, Nachit M, Lause P,
van Maanen A, Trefois P, Gruson D and Thissen JP: Circulating
Activin A predicts survival in cancer patients. J Cachexia
Sarcopenia Muscle. 8:768–777. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Seachrist DD and Keri RA: The Activin
social network: Activin, inhibin and follistatin in breast
development and cancer. Endocrinology. 160:1097–1110. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sobral LM, Bufalino A, Lopes MA, Graner E,
Salo T and Coletta RD: Myofbroblasts in the stroma of oral cancer
promote tumorigenesis via secretion of activin A. Oral Oncol.
47:840–846. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bufalino A, Cervigne NK, de Oliveira CE,
Fonseca FP, Rodrigues PC, Macedo CC, Sobral LM, Miguel MC, Lopes
MA, Paes Leme AF, et al: Low miR-143/miR-145 cluster levels induce
activin A overexpression in oral squamous cell carcinomas, which
contributes to poor prognosis. PLoS One. 10:e01365992015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kelner N, Rodrigues PC, Bufalino A,
Fonseca FP, Santos-Silva AR, Miguel MC, Pinto CA, Leme AF, Graner
E, Salo T, et al: Activin A immunoexpression as predictor of occult
lymph node metastasis and overall survival in oral tongue squamous
cell carcinoma. Head Neck. 37:479–486. 2015. View Article : Google Scholar
|
|
13
|
Maeshima K, Maeshima A, Hayashi Y, Kishi S
and Kojima I: Crucial role of activin a in tubulogenesis of
endo-thelial cells induced by vascular endothelial growth factor.
Endocrinology. 145:3739–3745. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wagner K, Peters M, Scholz A, Benckert C,
Ruderisch HS, Wiedenmann B and Rosewicz S: Activin A stimulates
vascular endothelial growth factor gene transcription in human
hepato-cellular carcinoma cells. Gastroenterology. 126:1828–1843.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bashir M, Damineni S, Mukherjee G and
Kondaiah P: Activin-A signaling promotes epithelial-mesenchymal
transition, invasion, and metastatic growth of breast cancer. NPJ
Breast Cancer. 1:150072015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Panopoulou E, Murphy C, Rasmussen H, Bagli
E, Rofstad EK and Fotsis T: Activin A suppresses neuroblastoma
xenograft tumor growth via antimitotic and antiangiogenic
mechanisms. Cancer Res. 65:1877–1886. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Krneta J, Kroll J, Alves F, Prahst C,
Sananbenesi F, Dullin C, Kimmina S, Phillips DJ and Augustin HG:
Dissociation of angio-genesis and tumorigenesis in follistatin- and
activin-expressing tumors. Cancer Res. 66:5686–5695. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kaneda H, Arao T, Matsumoto K, De Velasco
MA, Tamura D, Aomatsu K, Kudo K, Sakai K, Nagai T, Fujita Y, et al:
Activin A inhibits vascular endothelial cell growth and suppresses
tumour angiogenesis in gastric cancer. Br J Cancer. 105:1210–1217.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sawazaki-Calone I, Rangel A, Bueno AG,
Morais CF, Nagai HM, Kunz RP, Souza RL, Rutkauskis L, Salo T,
Almangush A, et al: The prognostic value of histopathological
grading systems in oral squamous cell carcinomas. Oral Dis.
21:755–761. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Agostini M, Almeida LY, Bastos DC, Ortega
RM, Moreira FS, Seguin F, Zecchin KG, Raposo HF, Oliveira HC,
Amoêdo ND, et al: The fatty acid synthase inhibitor orlistat
reduces the growth and metastasis of orthotopic tongue oral
squamous cell carcinomas. Mol Cancer Ther. 13:585–595. 2014.
View Article : Google Scholar
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
22
|
Salo T, Sutinen M, Hoque Apu E, Sundquist
E, Cervigne NK, de Oliveira CE, Akram SU, Ohlmeier S, Suomi F,
Eklund L, et al: A novel human leiomyoma tissue derived matrix for
cell culture studies. BMC Cancer. 15:9812015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
De Palma M, Biziato D and Petrova TV:
Microenvironmental regulation of tumour angiogenesis. Nat Rev
Cancer. 17:457–474. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chang KP, Kao HK, Liang Y, Cheng MH, Chang
YL, Liu SC, Lin YC, Ko TY, Lee YS, Tsai CL, et al: Overexpression
of activin A in oral squamous cell carcinoma: Association with poor
prognosis and tumor progression. Ann Surg Oncol. 17:1945–1956.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tsai CN, Tsai CL, Yi JS, Kao HK, Huang Y,
Wang CI, Lee YS and Chang KP: Activin A regulates the epidermal
growth factor receptor promoter by activating the PI3K/SP1 pathway
in oral squamous cell carcinoma cells. Sci Rep. 9:51972019.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Togashi Y, Kogita A, Sakamoto H, Hayashi
H, Terashima M, de Velasco MA, Sakai K, Fujita Y, Tomida S, Kitano
M, et al: Activin signal promotes cancer progression and is
involved in cachexia in a subset of pancreatic cancer. Cancer Lett.
356(2 Pt B): 819–827. 2015. View Article : Google Scholar
|
|
27
|
Hoda MA, Rozsas A, Lang E, Klikovits T,
Lohinai Z, Torok S, Berta J, Bendek M, Berger W, Hegedus B, et al:
High circulating activin A level is associated with tumor
progression and predicts poor prognosis in lung adenocarcinoma.
Oncotarget. 7:13388–13399. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jueckstock J, Burkhardt N, Kuhn C,
Blankenstein T, Mahner S, Schindlbeck C, Janni W, Rack B and
Mylonas I: Expression of activin during and after chemotherapy in
peripheral blood of patients with primary breast cancer. Anticancer
Res. 36:2153–2159. 2016.PubMed/NCBI
|
|
29
|
Staudacher JJ, Bauer J, Jana A, Tian J,
Carroll T, Mancinelli G, Özden Ö, Krett N, Guzman G, Kerr D, et al:
Activin signaling is an essential component of the TGF-β induced
pro-metastatic phenotype in colorectal cancer. Sci Rep. 7:55692017.
View Article : Google Scholar
|
|
30
|
Hayashi Y, Maeshima K, Goto F and Kojima
I: Activin A as a critical mediator of capillary formation:
Interaction with the fbroblast growth factor action. Endocr J.
54:311–318. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kalli M, Mpekris F, Wong CK, Panagi M,
Ozturk S, Thiagalingam S, Stylianopoulos T and Papageorgis P:
Activin A signaling regulates IL13Rα2 expression to promote breast
cancer metastasis. Front Oncol. 9:322019. View Article : Google Scholar
|
|
32
|
Donovan P, Dubey OA, Kallioinen S, Rogers
KW, Muehlethaler K, Müller P, Rimoldi D and Constam DB: Paracrine
activin-A signaling promotes melanoma growth and metastasis through
immune evasion. J Invest Dermatol. 137:2578–2587. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
McCarthy SA and Bicknell R: Inhibition of
vascular endothelial cell growth by activin-A. J Biol Chem.
268:23066–23071. 1993.PubMed/NCBI
|
|
34
|
Schramm A, von Schuetz V, Christiansen H,
Havers W, Papoutsi M, Wilting J and Schweigerer L: High activin
A-expression in human neuroblastoma: Suppression of malignant
potential and correlation with favourable clinical outcome.
Oncogene. 24:680–687. 2005. View Article : Google Scholar
|
|
35
|
Merfeld-Clauss S, Lu H, Wu X, March KL and
Traktuev DO: Hypoxia-induced activin A diminishes endothelial cell
vascu-logenic activity. J Cell Mol Med. 22:173–184. 2018.
View Article : Google Scholar
|
|
36
|
Fahmy-Garcia S, Farrell E, Witte-Bouma J,
Robbesom-van den Berge I, Suarez M, Mumcuoglu D, Walles H,
Kluijtmans SGJM, van der Eerden BCJ, van Osch GJVM, et al:
Follistatin effects in migration, vascularization, and osteogenesis
in vitro and bone repair in vivo. Front Bioeng Biotechnol.
7:382019. View Article : Google Scholar :
|
|
37
|
Kang HY, Huang HY, Hsieh CY, Li CF, Shyr
CR, Tsai MY, Chang C, Chuang YC and Huang KE: Activin A enhances
prostate cancer cell migration through activation of androgen
receptor and is overexpressed in metastatic prostate cancer. J Bone
Miner Res. 24:1180–1193. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Tahergorabi Z and Khazaei M: A review on
angiogenesis and its assays. Iran J Basic Med Sci. 15:1110–1126.
2012.
|
|
39
|
Levchenko T, Veitonmäki N, Lundkvist A,
Gerhardt H, Ming Y, Berggren K, Kvanta A, Carlsson R and Holmgren
L: Therapeutic antibodies targeting angiomotin inhibit angiogenesis
in vivo. FASEB J. 22:880–889. 2008. View Article : Google Scholar
|
|
40
|
Douglass S, Goyal A and Iozzo RV: The role
of perlecan and endorepellin in the control of tumor angiogenesis
and endothelial cell autophagy. Connect Tissue Res. 56:381–391.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Li Y, Zhu H, Klausen C, Peng B and Leung
PC: Vascular endothelial growth factor-A (VEGF-A) mediates activin
A-induced human trophoblast endothelial-like tube formation.
Endocrinology. 156:4257–4268. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Schuster C, Akslen LA, Stokowy T and
Straume O: Predictive value of angiogenic proteins in patients with
metastatic melanoma treated with bevacizumab monotherapy. J Pathol
Clin Res. 5:53–62. 2019. View Article : Google Scholar :
|
|
43
|
Caporarello N, Lupo G, Olivieri M,
Cristaldi M, Cambria MT, Salmeri M and Anfuso CD: Classical VEGF,
Notch and Ang signalling in cancer angiogenesis, alternative
approaches and future directions (Review). Mol Med Rep.
16:4393–4402. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Vempati P, Popel AS and Mac Gabhann F:
Extracellular regulation of VEGF: Isoforms, proteolysis, and
vascular patterning. Cytokine Growth Factor Rev. 25:1–19. 2014.
View Article : Google Scholar :
|
|
45
|
Zhao SF, Yang XD, Lu MX, Sun GW, Wang YX,
Zhang YK, Pu YM and Tang EY: Prognostic significance of VEGF
immuno-histochemical expression in oral cancer: A meta-analysis of
the literature. Tumour Biol. 34:3165–3171. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Cai C, Böttcher MC, Werner JA and Mandic
R: Differential expression of VEGF121, VEGF165 and VEGF189 in
angiomas and squamous cell carcinoma cell lines of the head and
neck. Anticancer Res. 30:805–810. 2010.PubMed/NCBI
|
|
47
|
Ehrbar M, Djonov VG, Schnell C, Tschanz
SA, Martiny-Baron G, Schenk U, Wood J, Burri PH, Hubbell JA and
Zisch AH: Cell-demanded liberation of VEGF121 from fibrin implants
induces local and controlled blood vessel growth. Circ Res.
94:1124–1132. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Nakatsu MN, Sainson RC, Pérez-del-Pulgar
S, Aoto JN, Aitkenhead M, Taylor KL, Carpenter PM and Hughes CC:
VEGF(121) and VEGF(165) regulate blood vessel diameter through
vascular endothelial growth factor receptor 2 in an in vitro
angiogenesis model. Lab Invest. 83:1873–1885. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Tozer GM, Kanthou C and Baguley BC:
Disrupting tumour blood vessels. Nat Rev Cancer. 5:423–435. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Shang B, Cao Z and Zhou Q: Progress in
tumor vascular normalization for anticancer therapy: Challenges and
perspectives. Front Med. 6:67–78. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Goel S, Duda DG, Xu L, Munn LL, Boucher Y,
Fukumura D and Jain RK: Normalization of the vasculature for
treatment of cancer and other diseases. Physiol Rev. 91:1071–1121.
2011. View Article : Google Scholar : PubMed/NCBI
|
